While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive ...

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | ...

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour ...

That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical ...

Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been ...

After a report of leaking product, Pfizer’s Hospira unit is pulling five lots of sterile injectable medicines from ...

When it comes to supporting cancer care and other therapeutic approaches in low- and middle-income countries (LMICs), Bristol ...

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by ...

Merck KGaA’s North American life science division, MilliporeSigma, has made U.S. | The U.S. Department of Justice on ...

This week’s episode of “The Top Line,” is the final part of a three-part series diving into the latest advancements in cell ...

The Bavencio-Inlyta combo showed a favorable trend, reducing the risk of death by 14% compared with Pfizer’s Sutent as a ...

As Johnson & Johnson sorts through a mountain of litigation claiming its talcum-based powders caused users to develop cancers ...